Ascendis Pharma AS (BSP:A1SN34) Other Financing: R$606 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:A1SN34 Ascendis Pharma AS BSP:A1SN34
55 GF Score
Price R$92.20
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Other Financing?

Ascendis Pharma AS BSP:A1SN34 55 Other Financing is R$606 Mil as of Mar. 2026. GuruFocus rates BSP:A1SN34 with a GF Score™ of 55/100. The stock has 5 warning signs investors should review.

Ascendis Pharma AS's Other Financing for the three months ended in Mar. 2026 was R$143 Mil.

Ascendis Pharma AS's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was R$606 Mil.

Ascendis Pharma AS Other Financing Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Other Financing Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.72 28.63 45.28 71.70 483.49

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.18 79.75 285.93 98.07 142.71
BSP:A1SN34
55GF Score
Ascendis Pharma AS BSP:A1SN34
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$606 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of R$606 Mil mean?
Ascendis Pharma AS (BSP:A1SN34) has a Other Financing of R$606 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Other Financing too high?
Ascendis Pharma AS's current Other Financing is R$606 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Other Financing compare to JAZZ and BBIO?
Ascendis Pharma AS's Other Financing of R$606 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Other Financing is R$606 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (BSP:A1SN34) has a current Other Financing of R$606 Mil. The current Other Financing is R$606 Mil. Ascendis Pharma AS's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Ascendis Pharma AS (BSP:A1SN34), the current Other Financing is R$606 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
55GF Score

Get the complete analysis for BSP:A1SN34

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$92.20
Price